Evidence map›Paper›PMID 21253359›Full record

ArticleExperimental diabetes research2011

Subthreshold α₂-adrenergic activation counteracts glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion.

Minglin Pan, Guang Yang, Xiuli Cui, Shao-Nian Yang

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Experimental diabetes research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Minglin PanTianjin Research Center of Basic Medical Sciences, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin, China.
Guang Yang
Xiuli Cui
Shao-Nian Yang
Tianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pancreatic β cell harbors α₂-adrenergic and glucagon-like peptide-1 (GLP-1) receptors on its plasma membrane to sense the corresponding ligands adrenaline/noradrenaline and GLP-1 to govern glucose-stimulated insulin secretion. However, it is not known whether these two signaling systems interact to gain the adequate and timely control of insulin release in response to glucose. The present work shows that the α₂-adrenergic agonist clonidine concentration-dependently depresses glucose-stimulated insulin secretion from INS-1 cells. On the contrary, GLP-1 concentration-dependently potentiates insulin secretory response to glucose. Importantly, the present work reveals that subthreshold α₂-adrenergic activation with clonidine counteracts GLP-1 potentiation of glucose-induced insulin secretion. This counteractory process relies on pertussis toxin- (PTX-) sensitive Gi proteins since it no longer occurs following PTX-mediated inactivation of Gi proteins. The counteraction of GLP-1 potentiation of glucose-stimulated insulin secretion by subthreshold α₂-adrenergic activation is likely to serve as a molecular mechanism for the delicate regulation of insulin release.

Indexed as

Adrenergic alpha-2 Receptor AgonistsAnimalsCell LineClonidineEnzyme InhibitorsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucoseGTP-Binding Protein alpha Subunits, Gi-GoHyperglycemiaInsulinInsulin-Secreting CellsInsulin SecretionLigandsOsmolar ConcentrationPertussis ToxinAdrenergic alpha-2 Receptor AgonistsClonidineEnzyme InhibitorsGlp1r protein, ratGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucoseGTP-Binding Protein alpha Subunits, Gi-GoInsulinLigandsPertussis ToxinProtein SubunitsReceptors, Adrenergic, alpha-2Receptors, Glucagon

Identifiers

PMID21253359
PMCPMC3021849
OpenAlexW2035983564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.